Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
APS discussing diagnostic test
-
Hello PAAB,
If a diagnostic test is required to determine eligibility for a drug, and we create a leave behind for HCPs explaining what the test is, how to order it, information on testing centres etc
- Either without mentioning the drug name at all, and not having any branding elements tying to the drug
- Or mentioning the drug name in a non-promotional, informational sense, also sans branding elements
Would such a piece be PAAB-exempt in one or both scenarios? Thanks for your guidance!
-
Good morning @supraja
An unbranded leave behind outlining a diagnostic test that is not exclusive to drug treatment and is part of the natural course of diagnosis and is being used as a standalone piece, may be considered exempt if it is limited to diagnosis (i.e. does not make mention of treatment or suggest treatment as a result of the test). Detailing/distributing this piece with branded content would render it subject to review (linkage principles). In the context of a branded piece and/or “mentioning a drug name in a non-promotional” context, the piece would not be exempt.
-
Good morning @supraja
An unbranded leave behind outlining a diagnostic test that is not exclusive to drug treatment and is part of the natural course of diagnosis and is being used as a standalone piece, may be considered exempt if it is limited to diagnosis (i.e. does not make mention of treatment or suggest treatment as a result of the test). Detailing/distributing this piece with branded content would render it subject to review (linkage principles). In the context of a branded piece and/or “mentioning a drug name in a non-promotional” context, the piece would not be exempt.
@jennifer-carroll Thanks very much, this is helpful!
